INTRODUCTION
The RAS (renin-angiotensin system) is an intricately coordinated hormonal cascade involved in cardiovascular control [1] with AngII (angiotensin II) as the main effector peptide regulating BP (blood pressure) regulation, and fluid and electrolyte homoeostasis. It is now widely accepted that AngII binds with high affinity to two distinct receptors: AT 1 R (angiotensin type 1 receptor) and AT 2 R (angiotensin type 2 receptor) [2] . AT 1 R activation mediates the 'classical' effects, including vasoconstriction, cellular growth and proliferation [2] . In contrast, AT 2 R activation counteracts AT 1 R-mediated actions, including vasodilatation, apoptosis and antigrowth effects [3] [4] [5] .
Far from being a simple linear system for the production of AngII, it is increasingly realized that other angiotensin metabolites of AngI (angiotensin I) and AngII can exert their own biological activity. These peptides include the C-terminal breakdown products of AngII, namely the heptapeptide AngIII [angiotensin III; angiotensin- (2) (3) (4) (5) (6) (7) (8) ] and the hexapeptide AngIV [angiotensin IV; angiotensin-(3-8)], as well as the Nterminal heptapeptide Ang-(1-7) [angiotensin- (1) (2) (3) (4) (5) (6) (7) ]. In most instances, these peptides evoke cardiovascular effects that are opposite to the classical effects of AngII [4, [6] [7] [8] [9] [10] [11] . There is also evidence that the effects of Ang-(1-7) and AngIV are via cognate receptors MasR (Mas receptor) and AT 4 R (angiotensin type 4 receptor)/IRAP (insulin-regulated aminopeptidase) respectively [12, 13] . However, there are many instances where the effects of Ang-(1-7) and AngIV are reported to act via their cognate receptors and/or AT 2 R [14] [15] [16] [17] [18] [19] [20] [21] . In addition, AngIII is thought to be the endogenous AT 2 R agonist in the kidney [7, 22] .
It has been postulated that shorter angiotensin peptides may act as endogenous AT 2 R ligands [4, 11] . We therefore undertook the first systematic examination of the relative AT 1 R-and AT 2 R-binding affinities of a number of endogenous angiotensin peptides, together with the currently available synthetic angiotensin receptor ligands. To this end, we have used HEK (human embryonic kidney)-293 cells stably transfected with either AT 1 R or AT 2 R and have determined the relative AT 2 R selectivity of AngII, AngIII, Ang-(1-7) and AngIV. In addition, we have tested the AT 2 R-selective agonists CGP42112 [23] and Compound 21 [24] , and the MasR ligands AVE0991 [25, 26] and A-779 [12, 27] . We hypothesized that some of the effects of Ang-(1-7) and AngIV that were inhibited by the AT 2 R antagonist PD123319 in functional cardiovascular studies [14] [15] [16] 21] may in fact be due to direct binding at AT 2 R. Furthermore, by performing these analyses within the one study, our results provide a benchmark reference for the relative rank order of AT 2 R/AT 1 R selectivity for a number of endogenous and synthetic angiotensin ligands.
MATERIALS AND METHODS
The generation of plasmids expressing HA (haemagglutinin)-tagged versions of AT 1 R and AT 2 R have been described previously [28, 29] . HEK-293 cells in 12-well plates were transfected with either AT 1 R or AT 2 R plasmids (0.6 μg/well) using Lipofectamine TM (4.8 μl/well), as described previously [30] , and stably expressing clones were obtained by selection with G418 (1 mg/ml) and limiting dilution.
HEK-293 stably transfected with either AT 1 R or AT 2 R [expressing equivalent amounts of receptors (∼1000 fmol/mg of protein)] were maintained in a humidified atmosphere in a CO 2 water-jacketed incubator (Forma Scientific) with 5 % CO 2 • C. After incubation, binding buffer was aspirated and unbound radioactivity was separated from bound radioligand by washing the wells with 250 μl of PBS. Each plate was aspirated once more and the cells were solubilized in 250 μl of 0.5 M NaOH for 10 min at room temperature (22
• C). The content of each well was transferred into appropriate tubes and the radioactivity was counted using a Wallac Wizard TM 1470 automatic γ -counter (PerkinElmer). Non-specific binding was defined in the presence of the unlabelled AngII (1 μM). Figure 1B and Table 1 ). By contrast, the MasR agonist AVE0991 and antagonist A-779 lacked affinity for both AT 1 R and AT 2 R, at least up to 1 μM (Figures 1A and 1B) .
RESULTS

Competition
In order to estimate the relative AT 2 R selectivities of the endogenous angiotensin peptides and synthetic ligands, the ratio of IC 50 values at AT 1 R/AT 2 R was determined (Figure 2 ). In the present study, AngII and AngIII were 15-and 33-fold selective for AT 2 R over AT 1 R. As expected, known AT 2 R ligands exhibited The results are derived from Figure 1 and Table 1 , and are plotted as a measure of the relative affinity of the angiotensin peptides and ligands for AT 1 R and AT 2 R. marked selectivity, ranging from 40 000-fold AT 2 R selectivity for CGP42112 to 4000-fold selectivity for Compound 21, whereas candesartan was at least 6000-fold selective for AT 1 R (Table 1) . AngIV and Ang-(1-7) exhibited a lower AT 2 R affinity relative to AngII and AngIII, but these peptides still had substantial AT 2 R selectivity over AT 1 R [that being 200-fold for AngIV and 40-fold for Ang-(1-7); Figure 2 ].
DISCUSSION
To address potential mismatches in functional and binding data, we have performed a systematic binding analysis in HEK-293 cells stably transfected either AT 1 R or AT 2 R, which has eliminated confounders such as tissue heterogeneity and differential angiotensin receptor expression when comparing ligands, both within and between published studies. Indeed, we have examined all of the major endogenous angiotensin peptide fragments and novel synthetic ligands in the one study, and have now shown that all endogenous angiotensin peptides tested have relatively greater AT 2 R selectivity over AT 1 R selectivity. Strikingly, we have found that AngIII has a similar affinity as AngII at AT 2 R, but at least 30-fold selectivity for AT 2 R over AT 1 R. Moreover, although Ang-(1-7) and AngIV exhibit ∼500-and 100-fold less affinity at AT 2 R compared with AngII, these peptides were 40-and 200-fold more selective for AT 2 R than AT 1 R. Collectively, the results of the present study have revealed the potential for all 'breakdown' products of AngII to act as endogenous ligands for AT 2 R.
As expected, candesartan and PD123319 behaved as highly selective AT 1 R and AT 2 R ligands respectively, consistent with actions as subtype-selective antagonists [2, 31, 32] . Moreover, near-identical angiotensin-receptorbinding selectivities have been reported for losartan and the related non-peptide AT 2 R ligand PD123177 in previous binding studies [33, 34] . In the present study, CGP42112 was >40 000-fold selective for AT 2 R over AT 1 R and had the highest affinity at AT 2 R of all of the ligands tested. In their original publication, Whitebread et al. [23] reported CGP42112 to have a nanomolar affinity at AT 2 R in rat and human uterus and adrenal tissue, and a micromolar affinity at AT 1 R, such that its AT 2 R selectivity ranged from approximately 1000-fold in rat uterus to 10 600-fold in human adrenal. Thus our findings using a homogenous cell expression system has revealed exquisite AT 2 R sensitivity for CGP42112.
More recently, a selective non-peptide AT 2 R agonist, Compound 21 [24] , has been developed, which is reported to evoke cardioprotective, anti-inflammatory [35] and vasodilator [36] effects. Initial characterization in pig uterine (AT 2 R) and rat liver (AT 1 R) membranes revealed K i values of 0.4 nM and >10 μM respectively, indicating >25 000-fold AT 2 R selectivity [24] . We showed a similar lack of AT 1 R affinity, but found that Compound 21 had an approximately 10-fold lower affinity than CGP42112 in AT 2 R-transfected HEK-293 cells. Nevertheless, Compound 21 was highly AT 2 Rselective (4000-fold).
In terms of angiotensin peptides, we have confirmed previous reports that AngII has high-binding affinity at both AT 1 R and AT 2 R [2, 23, [31] [32] [33] 37] , and that this octapeptide usually exhibits slight preferential affinity for AT 2 R [23, 33, 34] . In the present study, AngII was approximately 15 times more selective for AT 2 R compared with AT 1 R.
The C-terminal heptapeptide AngIII displaced 125 I-[Sar 1 Ile 8 ]AngII binding in AT 2 R-transfected HEK-293 cells in a similar manner to AngII, whereas, in some instances, AngIII is more potent at AT 2 R than AngII itself [31, 32, 37] . Nevertheless, given that AngIII exhibited a lower affinity for AT 1 R, AngIII was >30-fold selective for AT 2 R when compared with AT 1 R. These findings are consistent with the binding profile of AngIII in various tissues, thus providing clear evidence that AngIII is more selective at AT 2 R compared with AT 1 R [33, 38, 39] . In this context, it is noteworthy that AngIII evoked a natriuretic effect in rats via AT 2 R; an effect that was not observed using AngII [22] unless the metabolism of AngIII was inhibited [40] . These functional results indicate that AngIII may be an endogenous AT 2 R agonist in the kidney, which fits with our affinity profiling of AngIII as being AT 2 R-preferring. A similar finding that AngIII is the preferred AT 2 R agonist in the rat coronary vascular bed has also been postulated [41] .
Since the discovery of ACE2 (angiotensin-converting enzyme 2) [42] [43] [44] , there has been much interest in the functional effects of Ang-(1-7), which differ markedly to those of AngII [8, 10] . Indeed, evidence suggests that Ang-(1-7)-mediated effects are via a specific Ang-(1-7) receptor, known as the MasR [12, 45] . At the same time, there are many reports that Ang-(1-7) can mediate its effects via AT 2 R [8, 12, [18] [19] [20] 46, 47] . In fact, we have shown that the Ang-(1-7)-mediated vasodepressor effect was via AT 2 R stimulation [17] , in a similar manner to that seen with CGP42114 [48] and, more recently, Compound 21 [36] . Interestingly, in the present study, we observed substantial displacement of 125 I-[Sar 1 Ile 8 ]AngII by Ang-(1-7) in the AT 2 R-transfected HEK-293 cells, which is consistent with previous reports of this heptapeptide having low, but appreciable, affinity at AT 2 R in human myometrium [31] and transfected COS-7 cells [37] . Our present study also examined AT 1 R binding, and found that Ang-(1-7) exhibited minimal AT 1 R binding (at 1 μM). Thus, although Ang-(1-7) had nearly 500-fold less affinity than AngII at AT 2 R, it exhibited at least a 40-fold greater AT 2 R/AT 1 R selectivity, suggesting that, in addition to MasR activation, Ang-(1-7) is potentially an endogenous ligand at AT 2 R. In this context, we have recently reported that chronic treatment with Ang-(1-7) evoked both vaso-and athero-protective effects in ApoE (apolipoprotein E)-deficient mice that were sensitive to blockade by both MasR and AT 2 R antagonists [21] . By contrast, AVE099, the first non-peptide Ang-(1-7) mimetic and MasR agonist [12, 25, 26, 49, 50] , and the MasR antagonist A-779 [12] completely lacked affinity for either AT 1 R or AT 2 R in the present study. Thus the results of the present study would support an effect of Ang-(1-7) to directly stimulate AT 2 R as one possible mechanism to help explain the anti-atherosclerotic effects of Ang-(1-7) [21] .
Similarly to other angiotensin peptides, there is accumulating evidence suggesting the hexapeptide AngIV mediates its effects at AT 4 R, which is now thought to be identical with IRAP [13] , where AngIV inhibits catalytic activity. However, there are reports that the cardiovascular effects of AngIV are mediated via AT 4 R/IRAP and/or AT 2 R [14, 51, 52] . Indeed, we have shown that chronic AngIV treatment reversed endothelial dysfunction in atherosleclerosis, via both AT 2 R and AT 4 R [15, 16] . In the present study, AngIV exhibited marked binding at AT 2 R, with approximately 5-fold greater affinity than Ang-(1-7) and no appreciable AT 1 R binding (at 1 μM). This analysis revealed that AngIV was at least 200-fold more selective at binding to AT 2 R compared with AT 1 R.
Collectively, our rank order for AT 2 R binding [CGP42112>AngII AngIII>Compound 21 PD123319> >AngIV>Ang- (1) (2) (3) (4) (5) (6) (7) ] was similar to that obtained comparing CGP42112 and angiotensin peptides in human myometrium [31] and AT 2 R-transfected COS-7 cells [37] , except the order was reversed for AngIV and Ang-(1-7) in the latter two studies. In any case, the results of the present and previous studies emphasize that all angiotensin peptide fragments have considerable AT 2 R affinity and even those peptides that are reported to act via their cognate angiotensin receptor [AngIV and Ang-(1-7)] exhibit sub-micromolar affinity at AT 2 R. The ability of angiotensin peptides to act as potential AT 2 R ligands takes on greater significance if one considers that AT 2 Rs are up-regulated in many cardiovascular disease settings, including cardiac failure, cardiac fibrosis, renal failure, diabetes and atherosclerosis, and even aging (reviewed in [4, 11] ). Although AngII overactivity contributes to many cardiovascular pathologies, there may be an increased functional importance of AT 2 R, stimulated by AngII, or even shorter angiotensin peptide fragments, to limit AT 1 R-mediated overactivity and cardiovascular disease. Although less is known about changes in levels of angiotensin 'breakdown products' in cardiovascular disease, studies from our own laboratory highlight the potential importance of chronic effects of Ang-(1-7) and AngIV in atherosclerosis [16, 21] . In these studies, although both angiotensin peptide fragments acted via their respective cognate receptors, they also evoked vasoand athero-protective effects that were sensitive to AT 2 R blockade. Thus the results of the present binding studies implicate a direct AT 2 R activation.
A limitation of the present study is that we have used individual cell lines that were selected to express equivalent amounts of receptors, which may not reflect in vivo binding, where both AT 1 R and AT 2 R may be expressed on the same cell and at different expression levels. Our receptor expression levels (∼1000 fmol/mg of protein) were in the upper range of physiological levels, but these levels are likely to be achieved in various tissues, including adrenal, uterus, vascular smooth muscle and certain brain nuclei. Thus, although one must be cautious in extrapolating from artificial systems to in vivo conditions, our present results do allow relative affinity comparisons of ligands without confounders such as differential angiotensin receptor expression.
For the first time, we have provided an assessment of the relative AT 2 R/AT 1 R selectivity for all of the major endogenous angiotensin peptides and novel synthetic ligands currently available. This analysis showed the following AT 2 R/AT 1 R preference: CGP42112> >Compound 21>PD123319> > >AngIV> Ang-(1-7)∼AngIII>AngII> > >candesartan∼AVE0991 ∼A-779. Thus we have confirmed the marked AT 2 R selectivity of Compound 21 and have shown that the MasR ligand AVE0991 does not bind to AT 2 R. Finally, all of the endogenous angiotensin peptide fragments exhibited greater AT 2 R preference than AngII itself, adding further weight to the concept that these metabolites of AngII actually act in concert to oppose overactivity of the parent peptide AngII at AT 1 R. 
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